Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
June 25, 2021updated 22 Nov 2021 6:32am

LoA Update: Aimmune Therapeutics’ AR201 advancement chances increase as Phase II egg allergy study is completed

Aimmune Therapeutics' Phase II trial completion shifted AR201's Phase Transition Success Rate (PTSR) by 9 points to 11%, as of 21 June.

Aimmune Therapeutics’ Phase II trial completion shifted AR201’s Phase Transition Success Rate (PTSR) by 9 points to 11%, as of 21 June. Aimmune is a Nestle Health Science company, following its acquisition by the latter in August 2020.

The Phase II trial (NCT04056299), which is evaluating the oral desensitisation therapy regimen AR201 in people with a hen-egg allergy, was completed as per an 18 June update on the trial’s ClinicalTrials.gov entry. The first patient on this study was enrolled in mid-2019, as per a 21 August press release. AR201 is based on the company’s platform Characterised Oral Desensitisation ImmunoTherapy (CODIT) platform which involves desensitising patients with defined amounts of key allergens, thereby providing a meaningful level of protection against allergic reactions. Aimmune has an approval for its peanut allergy immunotherapy Palforzia, based on the same CODIT platform, under its belt.

The Phase II trial’s primary endpoint is measuring efficacy assessed by the highest tolerated dose of at least 1,000mg dried egg white protein given in a double-blind, placebo-controlled food challenge. While the trial is completed, study results have not yet been posted.

PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next. The PTSR score considers characteristics like therapy area, indication and molecule type, and is used to calculate a drug’s Likelihood of Approval (LoA), which in this case is 8% following a seven-point increase after the trial update.

Related Companies

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU